EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung Cancer

Author:

Yuan Ze1,Tao Dan1,Yang Dingyi1,Jiang Yong1,Munai Erha2,Zeng Siwei2,Wang Dehuan2,Wang Qiang2,Zhou Wei1,Wu Yongzhong1

Affiliation:

1. Department of Radiation Oncology, Chongqing University Cancer Hospital,

2. Medical School of Chongqing University, Chongqing University

Abstract

Abstract Background: Advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations presents a clinical challenge due to eventual resistance to EGFR tyrosine kinase inhibitors (TKIs). This study aimed to evaluate the efficacy and safety of combining EGFR-TKI therapy with stereotactic body radiotherapy (SBRT) to primary lesions in treating EGFR-mutant NSCLC patients. Methods: A retrospective analysis was conducted on 58 EGFR-mutant NSCLC patients treated between 2018 and 2023. Patients were divided into two groups: EGFR-TKI alone (n=43) and EGFR-TKI combined with SBRT (n=15). Clinical outcomes were assessed, including progression-free survival (PFS), overall survival (OS), and treatment-related toxicities. Statistical analyses were performed to compare the effectiveness of the treatment modalities. Results: A total of 485 patients with advanced NSCLC were screened, and 58 patients were eligible for enrollment in this study. Of the 58 eligible patients, 15 (25.9%) received EGFR-TKI treatment alone and 43(74.1%) received EGFR-TKI treatment plus with SBRT to lung primary tumor. The TKIs plus SBRT group exhibited a significant extension in PFS compared to the TKIs alone group (not reached vs 10.2 months, p < 0.001). Multivariate analysis identified SBRT as the sole significant positive predictor for PFS. Adverse event profiles were comparable between groups, with manageable toxicities and no Grade 4-5 events reported. Meta-analysis revealed that combined TKI and SBRT treatment significantly improved PFS (HR 0.39, 95% CI 0.24-0.64, P < 0.001) but showed no significant OS benefit. After excluding retrospective studies, a significant OS benefit was observed. (HR 0.47, 95% CI 0.33-0.69, P < 0.001). No increased incidence of grade ≥3 AEs with SBRT was observed, but the TKIs plus SBRT group had higher probabilities of pneumonitis and radiation dermatitis than the TKIs alone group. Conclusions: Our study suggests that the addition of SBRT to EGFR-TKI therapy significantly extends PFS and OS in EGFR-mutant NSCLC patients. The results emphasize the potential of combining local radiotherapy with targeted therapy, offering a promising approach to improve outcomes in this patient population.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3